1. Home
  2. CNOBP vs LYEL Comparison

CNOBP vs LYEL Comparison

Compare CNOBP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOBP

ConnectOne Bancorp Inc.

N/A

Current Price

$25.30

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$12.89

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNOBP
LYEL
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
320.1M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
CNOBP
LYEL
Price
$25.30
$12.89
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
5.1K
94.9K
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.51
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
$16.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.52
$11.47
52 Week High
$25.51
$45.00

Technical Indicators

Market Signals
Indicator
CNOBP
LYEL
Relative Strength Index (RSI) 60.87 38.74
Support Level $24.87 $11.87
Resistance Level $25.48 $14.14
Average True Range (ATR) 0.08 0.86
MACD 0.02 -0.22
Stochastic Oscillator 60.93 2.50

Price Performance

Historical Comparison
CNOBP
LYEL

About CNOBP ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: